News | January 05, 2022
Bharat Biotech's intranasal vaccine Phase 3 trials gets approval
It has also been granted permission to conduct trials for booster dose
It has also been granted permission to conduct trials for booster dose
The QuickVue antigen tests are able to detect the live Omicron variant with similar performance as with other variants
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
Flattish volume growth and subdued new launches were key factors for last month
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
EMA’s CHMP advice states that Paxlovid can be used for treatment of adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
Subscribe To Our Newsletter & Stay Updated
